2024
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Hajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.Peer-Reviewed Original ResearchAssessment of adverse eventsMild to moderate ADGamma oscillationsModerate ADAmyloid-related imaging abnormalitiesAlzheimer's diseaseMild-to-moderate Alzheimer's diseaseSecondary clinical outcome measuresTherapy systemPrimary outcome measureHigher adherence ratesWhole-brain volumeClinical outcome measuresSecondary outcome measuresModerate Alzheimer's diseaseDisease-modifying effectsBaseline MMSE scoreStudy discontinuationExperimental AD modelsWell-toleratedEfficacy outcomesClinical benefitAdverse eventsDaily treatmentClinical criteria
2021
Reduced brain atrophy by gamma sensory stimulation in Alzheimer’s disease patients
Hajos M, Megerian J, Hempel E, Vaughan B, Malchano Z. Reduced brain atrophy by gamma sensory stimulation in Alzheimer’s disease patients. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057849.Peer-Reviewed Original ResearchWhole brain volume lossBrain volumetric changesBrain volume lossBrain atrophyDisease patientsAlzheimer's disease patientsSensory stimulationAD patientsLateral ventriclePotential disease-modifying effectsAge-matched healthy subjectsDisease-modifying effectsAccelerated brain atrophyTemporal lobe volumeMild AD patientsMild-moderate ADMR imaging analysisMethods PatientsClinical presentationSame therapySham groupPatient populationVolume lossHippocampal volumeHealthy subjects
2020
Sensory‐evoked gamma frequency oscillations in Alzheimer’s disease patients: Biomarker and therapeutic applications
Hajos M, Harvey B, Mortimore H, Strozewski N, Kolin K, Boasso A, Cimenser A, Marin A, Hajos G, Palumbo R, Spencer K, Malchano Z, Budson A. Sensory‐evoked gamma frequency oscillations in Alzheimer’s disease patients: Biomarker and therapeutic applications. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043937.Peer-Reviewed Original ResearchAD patientsDisease patientsHealthy young subjectsAlzheimer's disease patientsHealthy subjectsYoung subjectsInter-trial coherenceElderly subjectsVisual stimulationMCI/AD patientsNeuronal network integrityAD-related pathologyDisease-modifying effectsTest/re-test reliabilityHealthy elderly subjectsHz stimulation frequencyHealthy elderly individualsFronto-temporal regionsLight stimulationGamma frequency oscillationsAdverse eventsRe-test reliabilityHz stimulationElderly individualsPatients
2017
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Smith LM, Zhu R, Strittmatter SM. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model. Neuropharmacology 2017, 130: 54-61. PMID: 29191754, PMCID: PMC5743608, DOI: 10.1016/j.neuropharm.2017.11.042.Peer-Reviewed Original ResearchConceptsAlzheimer's modelDisease-modifying effectsDisease-modifying therapiesMouse Alzheimer’s modelsTherapy withdrawalAPPswe/Investigational agentsSynapse densityDrug washoutTransgenic modelAlzheimer's diseasePersistent benefitsPersistent improvementSaracatinibFyn inhibitorMemantineLoss of benefitDiseaseSpatial memoryMemory functionWashoutTherapySymptomsMiceWeeks
2014
Interleukin-23 receptor single nucleotide polymorphisms in ulcerative colitis. A study in Iranian populations
Ebrahimi Daryani N, Najmi Varzaneh F, Hedayat M, Taher M, Farhadi E, Mahmoudi M, Nicknam M, Bashashati M, Rezaei N. Interleukin-23 receptor single nucleotide polymorphisms in ulcerative colitis. A study in Iranian populations. Clinics And Research In Hepatology And Gastroenterology 2014, 38: 360-365. PMID: 24485526, DOI: 10.1016/j.clinre.2013.12.008.Peer-Reviewed Original ResearchConceptsIL23R single-nucleotide polymorphismsReceptor single nucleotide polymorphismsUlcerative colitisGroup of patientsSingle nucleotide polymorphismsPatient groupIranian adult patientsDisease-modifying effectsFuture therapeutic interventionsReal-time polymerase chain reactionAdult patientsCrohn's diseasePolymerase chain reactionHealthy controlsNucleotide polymorphismsTT genotypeTherapeutic interventionsIranian populationPatientsT alleleSignificant associationGenetic factorsDiseaseChain reactionGenotype frequencies
2009
Subregional neuroanatomical change as a biomarker for Alzheimer's disease
Holland D, Brewer J, Hagler D, Fennema-Notestine C, Dale A, Weiner M, Thal L, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Gamst A, Potter W, Montine T, Anders D, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Shaw L, Lee V, Korecka M, Crawford K, Neu S, Harvey D, Kornak J, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Vorobik R, Quinn J, Schneider L, Pawluczyk S, Spann B, Fleisher A, Vanderswag H, Heidebrink J, Lord J, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Mintun M, Schneider S, Marson D, Griffith R, Badger B, Grossman H, Tang C, Stern J, deToledo-Morrell L, Shah R, Bach J, Duara R, Isaacson R, Strauman S, Albert M, Pedroso J, Toroney J, Rusinek H, de Leon M, De Santi S, Doraiswamy P, Petrella J, Aiello M, Clark C, Pham C, Nunez J, Smith C, Given C, Hardy P, DeKosky S, Oakley M, Simpson D, Ismail M, Porsteinsson A, McCallum C, Cramer S, Mulnard R, McAdams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Laubinger M, Bartzokis G, Silverman D, Lu P, Fletcher R, Parfitt F, Johnson H, Farlow M, Herring S, Hake A, van Dyck C, MacAvoy M, Bifano L, Chertkow H, Bergman H, Hosein C, Black S, Graham S, Caldwell C, Feldman H, Assaly M, Hsiung G, Kertesz A, Rogers J, Trost D, Bernick C, Gitelman D, Johnson N, Mesulam M, Sadowsky C, Villena T, Mesner S, Aisen P, Johnson K, Behan K, Sperling R, Rentz D, Johnson K, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Obradov S, Killiany R, Norbash A, Obisesan T, Jayam-Trouth A, Wang P, Auchus A, Huang J, Friedland R, DeCarli C, Fletcher E, Carmichael O, Kittur S, Mirje S, Johnson S, Borrie M, Lee T, Asthana S, Carlsson C, Potkin S, Highum D, Preda A, Nguyen D, Tariot P, Hendin B, Scharre D, Kataki M, Beversdorf D, Zimmerman E, Celmins D, Brown A, Gandy S, Marenberg M, Rovner B, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Pare N, Williamson J, Sink K, Potter H, Raj B, Giordano A, Ott B, Wu C, Cohen R, Wilks K, Safirstein B. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 20954-20959. PMID: 19996185, PMCID: PMC2791580, DOI: 10.1073/pnas.0906053106.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentAlzheimer's diseaseClinical trialsOutcome measuresCerebral volume changesDisease-modifying effectsCerebral structural changesDisease-modifying agentsSerial MRI scansTemporal lobe cortical regionsSensitive outcome measuresDisease-related changesBrain atrophyNeuroprotective effectsAD pathologyHealthy controlsSubregional atrophyCortical changesEarly diagnosisNeuroanatomical changesCortical thicknessNormal subjectsMRI scansVentricular volumeClinical practice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply